Cordis Corporation (JNJ) Release: INCRAFT AAA Stent-Graft System One-Year Follow-Up Data Presented at 2012 Veith Symposium
11/20/2012 9:05:23 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cordis Corporation today announced the presentation of the INCRAFT™ AAA Stent-Graft System INNOVATION study one-year results at the 2012 Veith Symposium in New York City. Investigator Professor Gioachino Coppi, MD, from the University of Modena and Reggio Emilia in Italy, presented the results of the INNOVATION study (A MULTICENTER, OPEN LABEL, PROSPECTIVE, NON-RANDOMIZED STUDY OF INCRAFT™ IN SUBJECTS WITH ABDOMINAL AORTIC ANEURYSMS) on behalf of the study investigators. The INNOVATION study assesses the safety and efficacy of the INCRAFT™ System in treating patients with abdominal aortic aneurysms (AAA) at investigational sites in Germany and Italy. An estimated 24 million people worldwide have abdominal aortic aneurysms. Left untreated, most aneurysms will eventually rupture, with life-threatening consequences. In the U.S. alone, approximately 15,000 people die every year due to an AAA rupture.
comments powered by